Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of LY09004 vs Eylea in Wet Age-related Macular Degeneration
NCT04572698Phase 3Unknown
- Sponsor
- Luye Pharma Group
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in exudative macular degeneration (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Best Corrected Visual Acuity at Week 24. Status: unknown.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04572698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572698.